A detailed history of Oppenheimer & CO Inc transactions in Chroma Dex Corp. stock. As of the latest transaction made, Oppenheimer & CO Inc holds 19,600 shares of CDXC stock, worth $53,508. This represents 0.0% of its overall portfolio holdings.

Number of Shares
19,600
Previous 27,600 28.99%
Holding current value
$53,508
Previous $39,000 74.36%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 06, 2024

SELL
$1.36 - $3.84 $10,880 - $30,720
-8,000 Reduced 28.99%
19,600 $68,000
Q1 2023

May 10, 2023

SELL
$1.48 - $2.19 $3,700 - $5,475
-2,500 Reduced 8.31%
27,600 $42,000
Q4 2022

Feb 07, 2023

SELL
$1.46 - $1.94 $146 - $194
-100 Reduced 0.33%
30,100 $50,000
Q3 2022

Nov 14, 2022

SELL
$1.21 - $2.06 $10,781 - $18,354
-8,910 Reduced 22.78%
30,200 $37,000
Q2 2022

Aug 08, 2022

BUY
$1.59 - $2.7 $34,821 - $59,130
21,900 Added 127.25%
39,110 $65,000
Q1 2022

May 12, 2022

SELL
$2.02 - $3.92 $15,958 - $30,968
-7,900 Reduced 31.46%
17,210 $42,000
Q4 2021

Feb 02, 2022

BUY
$3.74 - $6.7 $10,846 - $19,430
2,900 Added 13.06%
25,110 $94,000
Q2 2021

Aug 03, 2021

BUY
$6.66 - $10.92 $17,316 - $28,392
2,600 Added 13.26%
22,210 $219,000
Q1 2021

May 10, 2021

SELL
$4.59 - $18.74 $17,901 - $73,086
-3,900 Reduced 16.59%
19,610 $183,000
Q4 2020

Feb 11, 2021

BUY
$3.93 - $5.5 $92,394 - $129,305
23,510 New
23,510 $113,000
Q1 2019

Apr 24, 2019

SELL
$3.2 - $4.19 $160,000 - $209,500
-50,000 Closed
0 $0
Q4 2018

Jan 29, 2019

SELL
$2.8 - $4.22 $118,999 - $179,350
-42,500 Reduced 45.95%
50,000 $172,000
Q1 2018

May 01, 2018

BUY
$4.05 - $6.46 $202,500 - $323,000
50,000 Added 117.65%
92,500 $389,000
Q4 2017

Feb 07, 2018

BUY
$3.88 - $6.96 $164,900 - $295,800
42,500
42,500 $250,000

Others Institutions Holding CDXC

About ChromaDex Corp.


  • Ticker CDXC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,350,896
  • Market Cap $187M
  • Description
  • ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingre...
More about CDXC
Track This Portfolio

Track Oppenheimer & CO Inc Portfolio

Follow Oppenheimer & CO Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

News

Stay updated on Oppenheimer & CO Inc with notifications on news.